The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions. Against this backdrop Drug Discovery 2017 will provide a platform to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

The conference will bring together industry leaders who will highlight future opportunities for novel therapeutic discovery. Some of our featured speakers include

• Lorenz Mayr, VP & Global Head, AstraZeneca
• Guido Hanaeur, Scientific Director Translational Medicine, Takeda
• Ulrich Schopfer, Executive Director, Head Integrated Lead Discovery, Novartis
• Yolanda Chong, Principal Scientist, Johnson & Johnson
• Matthias Frech, Director, Molecular Interactions & Biophysics, Merck Serono
• Wengard Czechtizky, Head of Chemistry, Sanofi
• Ulrich Schopfer, Executive Director, head Integrated Lead Discovery, Novartis
• Stephen Pickett, Senior Scientific Investigator, GSK

Plus more from AbbVie, UCB Pharma, Eli Lilly, TissUse, Heptares etc.

Key Highlights:

• discussions on the use of CRISPR/Cas9 Technology in target discovery, hit finding and translational studies;
• success stories on phenotyping screening;
• debates as to whether translational medicine is capable of increasing success rate in pharma;
• insights into receptor activation from agonist and antagonist structures;
• examples of applications of enabling chemistry technology to the acceleration of the drug discovery process.

For more information and to register, kindly visit http://www.drug-discovery.co.uk/euagenda.